Akomera

Cover Block

Open sources

Attribute	Details
Name	Akomera
Tagline	Developing a noninvasive wearable device to reduce chemotherapy-related hearing damage in cancer patients.
Headquarters	Houston, United States
Founded	2026
Stage	Pre-Seed
Industry	Healthtech
Technology	Hardware
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Pre-seed
Total Disclosed	~$70,000 [F6S, September 2026]

Links

Open sources

• Website: https://akomera.com
• LinkedIn: https://www.linkedin.com/in/sarahkusumo/

What an Investor Needs First

Open sources

Akomera is a pre-seed medtech startup developing a noninvasive wearable to prevent hearing damage in cancer patients, a specific and underserved complication of chemotherapy that creates a clear wedge into a high-stakes clinical setting [F6S, January 2026]. Founded in 2026 by Sarah Kusumo, the company is currently prototyping its device while navigating the early stages of intellectual property and regulatory strategy. The product aims to offer localized, targeted protection during chemotherapy infessions, differentiating it from post-symptom management approaches [F6S, January 2026].

Kusumo's background as a new-product-development R&D engineer and her participation in prominent accelerators like TMC Innovation and MedTech Innovator provide a relevant foundation in medical device development, though the venture is still solo-founded [LinkedIn, September 2026]. To date, Akomera has raised approximately $70,000 from the Texas Medical Center, a strategic, non-dilutive source of capital that aligns with its Houston location and clinical focus [F6S, September 2026]. Over the next 12-18 months, investor attention should focus on the transition from prototype to a defined regulatory pathway, the securing of initial clinical validation data, and the expansion of the founding team beyond its current solo structure.

Partially corroborated -- Core company details and founder background are confirmed; product claims and funding specifics rely on a single directory source.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Industry / Vertical	Healthtech
Technology Type	Hardware
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Pre-seed (total disclosed ~$70,000)

Inside the Company

Open sources

Akomera was established in 2026 in Houston, Texas, with the aim of addressing chemotherapy-induced hearing loss through a wearable device. Founder Sarah Kusumo brought a background in biomedical engineering and medical device R&D from her time at Medtronic to the venture [LinkedIn, September 2026].

The company's early trajectory includes selection for the TiE Houston founder program in July 2026, followed by a reported $70,000 in funding from the Texas Medical Center later that year [TiE Houston, July 2026] [F6S, September 2026]. Public records do not yet show a formal incorporation filing or detailed capitalization table on Crunchbase.

Partially corroborated -- Core facts rely on accelerator announcements and a single funding directory; founder background is corroborated by professional profile.

Under the Hood

Reported and inferred Akomera's public product description is a concise statement of intent, not a detailed technical specification. The company is developing a noninvasive, locally targeted wearable device intended for use by cancer patients during platinum-based chemotherapy infusion sessions [F6S, January 2026]. The core value proposition is to reduce ototoxicity, the hearing and balance damage that is a known side effect of these life-saving drugs.

The mechanism of action and the specific technology enabling this localized protection are not publicly disclosed. The available profile states the company is actively prototyping the device and working on intellectual property, regulatory, and reimbursement strategies, which frames the current stage as pre-clinical development [F6S, January 2026]. No information on device form factor, power source, sensor types, or data connectivity is available from indexed sources.

Reasoned from indirect evidence -- Product claims are sourced solely from a single company profile; no third-party technical validation or detailed specifications are available.

Market Research

Open sources The market for interventions that prevent chemotherapy-induced hearing loss is gaining relevance as oncology shifts towards minimizing long-term treatment side effects.

Ototoxicity is a notable sequela of cancer treatment, with symptoms including hearing loss, vertigo, dizziness, and tinnitus impacting patient quality of life [PMC, 2026]. The severity of these symptoms varies based on factors such as patient age, the specific chemotherapeutic agent used, dosage, and administration method, indicating a heterogeneous patient population that may require tailored protective measures [PMC, 2026].

Demand drivers for otoprotective devices include the increasing global incidence of cancer and a growing focus on survivorship care that prioritizes long-term patient outcomes. The adoption of wearable medical technology in clinical settings provides a tailwind, though specific market sizing data for this niche is not publicly available in the cited sources. Adjacent markets, such as hearing aids and general supportive care products, offer analogous demand but do not directly address prevention during chemotherapy infusion.

Regulatory and macro forces will significantly shape market entry. The device will likely need clearance as a Class II medical device through the FDA's 510(k) or De Novo pathways, and reimbursement strategies must align with oncology care protocols to ensure adoption by healthcare systems.

Partially corroborated -- Ototoxicity prevalence and characteristics are sourced from medical literature [PMC, 2026]; market sizing and demand drivers lack independent verification.

Competition and Substitutes

Reported and inferred

Akomera's competitive position is defined by its attempt to intercept a specific, acute side effect of cancer treatment with a noninvasive device, a strategy that places it between established pharmaceutical interventions and passive hearing rehabilitation.

The competitive landscape for ototoxicity management is fragmented, with players operating in distinct segments. The pharmaceutical segment includes companies like Fennec Pharmaceuticals, which markets Pedmark (sodium thiosulfate), an FDA-approved intravenous drug administered alongside chemotherapy to reduce the risk of cisplatin-induced hearing loss in pediatric patients [Labiotech.eu, 2026]. This represents a direct, systemic pharmacological approach. In the biotechnology and therapeutic segment, Sensorion is a clinical-stage company developing gene therapies and small molecules for inner ear disorders, targeting a range of hearing loss etiologies beyond chemotherapy [Labiotech.eu, 2026]. Adjacent substitutes include the broader market for hearing aids and cochlear implants, which address hearing loss after it has occurred, and supportive care protocols within oncology that may involve audiometric monitoring and dose adjustments.

Akomera's stated edge is its form factor and timing. The company's proposed wearable aims for localized, noninvasive protection delivered specifically during the infusion session, a point of intervention that is distinct from a systemic drug or a post-facto rehabilitation device [F6S, January 2026]. This edge is currently conceptual and perishable; it hinges entirely on the unproven clinical efficacy of the prototype and its ability to secure regulatory clearance as a medical device. A durable advantage would require building proprietary intellectual property around the device's mechanism and demonstrating superior patient compliance or cost-effectiveness compared to intravenous drugs.

The company is most exposed on two fronts. First, it faces the significant regulatory and commercial moat of an already-approved drug. Fennec's Pedmark has established clinical data, a defined reimbursement pathway, and integration into pediatric oncology treatment protocols, creating a high barrier for a novel device to demonstrate non-inferiority or a compelling enough improvement to shift practice. Second, Akomera's solo-founder structure and minimal disclosed capital of $70,000 leave it resource-constrained against well-funded biotechs like Sensorion, which can pursue multiple therapeutic pathways and advanced clinical trials [F6S, September 2026].

The most plausible 18-month scenario involves increased specialization within the niche. If Akomera can generate preliminary clinical data demonstrating safety and a measurable protective effect, it could position itself as a candidate for combination therapy or for patient populations where systemic drug administration is contraindicated. In this scenario, the "winner" would be a company like Fennec that solidifies its standard-of-care status, while the "loser" would be any early-stage entrant, including Akomera, that fails to transition from prototype to pivotal trial due to capital or clinical validation shortfalls. The competitive map will likely clarify as Akomera's technology moves from concept to data.

Partially corroborated -- Competitor profiles are publicly documented, but Akomera's product claims and differentiation are sourced solely from a company directory.

Opportunity

Open sources If Akomera can prove its device meaningfully reduces a debilitating side effect for millions of cancer patients, the commercial and clinical prize is substantial, extending beyond a single product to a new standard of care in supportive oncology.

The headline opportunity is to become the first approved, noninvasive standard-of-care intervention for chemotherapy-induced ototoxicity, a category currently defined by reactive management and a single approved drug. The evidence that makes this outcome reachable, rather than purely aspirational, lies in the acute, unmet clinical need and the founder's deliberate positioning within the medical innovation ecosystem. Ototoxicity is a documented and often permanent sequela of platinum-based chemotherapy, with symptoms ranging from hearing loss to debilitating tinnitus and vertigo [PMC, 2026]. The current standard involves monitoring and, in some cases, the use of sodium thiosulfate (marketed by Fennec Pharmaceuticals), which is administered intravenously and carries its own logistical and cost burdens. Akomera's wedge, a locally targeted wearable used during the infusion itself, proposes a preventive, patient-administered alternative. Founder Sarah Kusumo's background in medical device R&D and her residency within the Texas Medical Center's innovation program [LinkedIn, September 2026] suggest a path to navigating the complex regulatory and clinical validation required to turn this concept into a reimbursable medical device.

Growth from a prototype to a category-defining asset would likely follow one of several concrete paths, each hinging on a specific, near-term catalyst.

Scenario	What happens	Catalyst	Why it's plausible
Oncology Clinic Adoption	The device is adopted as a clinic-provided service to differentiate care and improve patient quality-of-life metrics, billed under a CPT code.	Successful pilot study data presented at ASCO or a similar oncology conference.	The focus on patient experience and reducing long-term morbidity aligns with value-based care incentives in oncology. Participation in MedTech Innovator [LinkedIn, September 2026] provides access to key opinion leaders and potential pilot sites.
Pharmaceutical Partnership	A pharma company licenses or co-develops the device as a companion product to its platinum-based chemotherapy drug to reduce side effects and improve drug tolerability.	Strategic grant or development partnership from a drug manufacturer's patient-support division.	Drug makers have a vested interest in mitigating the side-effect profiles of their therapies. Akomera's early-stage positioning and TMC affiliation [F6S, September 2026] make it a plausible partner for exploratory collaborations.

Compounding success in this field would not be driven by a classic software network effect, but by the accumulation of clinical evidence and integration into treatment protocols. Each successful clinical deployment generates more patient outcome data, strengthening the regulatory dossier for label expansions (e.g., broader patient populations, different chemotherapies) and improving the value proposition for payers. This data moat would be difficult for a new entrant to replicate without years of controlled studies. Furthermore, adoption within a major hospital system or network could create a form of distribution lock-in, as standardized supportive care protocols are slow to change, and clinician familiarity with a specific device builds institutional preference.

The size of the win, should a dominant scenario play out, can be framed by looking at the market for the problem, not just the device. The sole approved drug for preventing cisplatin-induced hearing loss, Fennec Pharmaceuticals' Pedmark, reported net product revenue of $34.5 million for the full year 2025 [Fennec Pharmaceuticals, March 2026]. This provides a tangible, if early, commercial comparable for a single-indication supportive care product. A successful medical device achieving similar penetration, but with a potentially superior safety and administration profile, could command significant value. In a pharmaceutical partnership scenario, the win could resemble a strategic acquisition where the device technology is valued for its ability to enhance an existing drug's commercial potential, a dynamic seen in other areas of supportive care. This is a scenario-based outcome, not a forecast, but it grounds the opportunity in the economic activity already occurring in the adjacent market.

Partially corroborated -- The clinical need and market dynamics are supported by published research and a public competitor's financials. Akomera's specific path and product claims are sourced from early-stage directory listings and founder profiles, which lack third-party verification.

Sources

Open sources

1. [F6S, January 2026] Akomera | https://www.f6s.com/akomera

2. [LinkedIn, September 2026] Sarah Kusumo - Akomera, Inc. | https://www.linkedin.com/in/sarahkusumo/

3. [TiE Houston, July 2026] TiE Houston Announces 2026 Founder Program Participants | https://houston.tie.org/news/tie-houston-announces-2026-founder-program-participants/

4. [F6S, September 2026] 23 Top Biotech Companies in Houston | https://www.f6s.com/companies/biotech/houston

5. [PMC, 2026] Hearing loss during chemotherapy: prevalence, mechanisms, and protection - PMC | https://pmc.ncbi.nlm.nih.gov/articles/PMC11477841/

6. [Labiotech.eu, 2026] 5 hearing loss biotech companies you should know about | https://www.labiotech.eu/best-biotech/hearing-loss-companies/